A study published in Circulation: Cardiovascular Interventions shows that robotic percutaneous coronary intervention with the CorPath GRX system (Corindus Vascular Robotics, Siemens Healthineers) reduces patient exposure to radiation by 20% compared to manual PCI with no increase in fluoroscopy time or contrast use.
The paper discusses the study of 996 consecutive patients, of which 310 underwent robotic PCI and 686 underwent manual PCI. The study sought to measure air kerma (AK), dose area product (DAP), fluoroscopy time, volume of contrast and total procedural time. Tejas Patel (Apex Heart Institute in Ahmedabad, Gujarat, India), the lead investigator of the study, says: “These findings further represent the benefits of robotic-assisted intervention, particularly for patients. The application of vascular robotics has shown other benefits through added precise device manipulation, and now, creates a safer environment for patients. I am honoured to share my experience with the clinical community and to offer the benefits of this technology to my patients.”
According to a press release, the CorPath GRX design protects physicians by removing them from the radiation field and has been shown to reduce radiation exposure by over 95%. The press release states Patel et al’s data prove robotic intervention also provides significant health benefits to patients by limiting radiation exposure as compared to a manual procedure.
Mark Toland, CEO of Corindus, comments: “The power of robotic intervention lies in its ability to increase patient and physician safety and improve clinical outcomes for delicate cardiovascular procedures. Dr Patel’s study validated our core beliefs and demonstrated a notable clinical benefit for patients undergoing robotic procedures. We see tremendous potential in health care to continue to make treatment paradigms safer and more effective through robotics and look forward to playing a significant role in that evolution.”
